13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
52 檔
17.5%
At the close of Q1 2024, Opaleye Management Inc. disclosed equity holdings valued at approximately $1.1B, spread across 52 reported holdings.
During Q1 2024, Opaleye Management Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, HROW, TGTX) accounted for 17.5% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 13.19% | -0.14% | +9.61% | |
| 2 | HROW | Harrow Inc | Stock-Other | 11.30% | -3.92% | +2.63% | |
| 3 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 7.56% | +0.32% | +2.93% | |
| 4 | KROS | Keros Therapeutics Inc | Stock-Other | 5.30% | — | +2.80% | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.86% | -3.42% | -15.57% | |
| 6 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 3.49% | — | -20.11% | |
| 7 | ARVN | Arvinas Inc | Stock-Other | 2.97% | — | +25.14% | |
| 8 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 2.90% | — | — | |
| 9 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.79% | — | — | |
| 10 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.64% | -0.23% | -4.86% | |
| 11 | APLT | Applied Therapeutics Inc | Stock-Other | 2.62% | — | +62.01% | |
| 12 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.39% | +0.26% | +11.55% | |
| 13 | CDXS | Codexis Inc | Stock-Other | 2.37% | -0.07% | +2.45% | |
| 14 | TARA | Protara Therapeutic Inc | Stock-Other | 2.35% | — | — | |
| 15 | ✓ | Acelyrin Inc | Stock-Other | 2.32% | — | -61.89% | |
| 16 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.14% | — | -31.71% | |
| 17 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 2.00% | +0.08% | -3.32% | |
| 18 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.99% | -0.02% | +4.34% | |
| 19 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 1.63% | — | — | |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.63% | — | +18.84% | |
| 21 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.54% | — | +12.72% | |
| 22 | NTLA | Intellia Therapeutics Inc | Stock-Other | 1.53% | -0.03% | +157.58% | |
| 23 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.37% | — | — | |
| 24 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.31% | +0.06% | — | |
| 25 | LQDA | Liquidia CORP | Stock-Other | 1.27% | +5.97% | -11.24% | |
| 26 | PCVX | Vaxcyte Inc | Stock-Other | 1.27% | — | -5.56% | |
| 27 | ✓ | Nyxoah S A | Stock-Other | 0.94% | — | -7.19% | |
| 28 | SVRA | Savara Inc | Stock-Other | 0.93% | — | — | |
| 29 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.92% | — | +119.15% | |
| 30 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.88% | +1.41% | -15.63% | |
| 31 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.86% | — | — | |
| 32 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 0.84% | — | — | |
| 33 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.77% | -0.27% | -13.46% | |
| 34 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.71% | -0.28% | — | |
| 35 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 0.70% | — | — | |
| 36 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.69% | +0.18% | — | |
| 37 | ALLKGUSD | Allakos Inc | Stock-Other | 0.67% | — | — | |
| 38 | GOSS | Gossamer Bio Inc | Stock-Other | 0.63% | — | -18.18% | |
| 39 | IBIO | Ibio Inc | Stock-Other | 0.60% | — | — | |
| 40 | VSTM | Verastem Inc | Stock-Other | 0.54% | +0.62% | NEW | |
| 41 | ✓ | Aligos Therapeutics Inc | Stock-Other | 0.35% | — | +25.67% | |
| 42 | CNTX | Context Therapeutics Inc | Stock-Other | 0.33% | — | +13.68% | |
| 43 | PGEN | Precigen Inc | Stock-Other | 0.30% | — | -6.42% | |
| 44 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.29% | — | -72.03% | |
| 45 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 46 | MOR2 | Morphosys AG Adr | Stock-Other | 0.26% | — | -55.17% | |
| 47 | GKOS | Glaukos CORP | Stock-Healthcare | 0.18% | — | — | |
| 48 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.17% | — | — | |
| 49 | ✓ | Biodesix Inc | Stock-Other | 0.17% | — | +7.69% | |
| 50 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.11% | — | — |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 52 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Opaleye Management Inc.'s top holdings by market value included OCUL (13.2%)、HROW (11.3%)、TGTX (7.6%). The largest single position, OCUL, represented 13.2% of total portfolio value.
In Q1 2024, Opaleye Management Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.